Months af­ter big fi­nanc­ing round, Touch­light signs sup­ply agree­ment for Ver­same­b's pipeline

A UK-based CD­MO has land­ed a sup­ply agree­ment with Ver­sameb to pro­vide its dog­gy­bone DNA for the com­pa­ny’s pipeline, in­clud­ing for its lead can­di­date to treat stress uri­nary in­con­ti­nence.

Touch­light will sup­ply Ver­sameb with its en­zy­mat­ic DNA as the biotech pre­pares to en­ter VMB-100 in­to Phase I clin­i­cal tri­als in the sec­ond half of this year. The deal will al­low Ver­sameb to uti­lize Touch­light’s dbD­NA, al­so called dog­gy­bone DNA, for all fu­ture pipeline prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER